Are These 28 European Countries About to Open the Door to Monsanto Company?

New policy in Europe concerning biotech crops could create the next wave of growth for Monsanto Company, Syngenta, and The Dow Chemical Company.

Jul 20, 2014 at 1:16PM


Will GMOs soon be as synonymous with Europe as vineyards? Source: Andrei Stroe/ Wikimedia Commons.

Europe has long taken a precautionary approach when dealing with biotech crops. Twenty-eight of the 64 countries globally that require labels for food products containing ingredients produced from genetically modified organisms reside in the European Union. And, while the import and cultivation of biotech crops is only banned outright in one European nation, only five European Union members -- the Czech Republic, Portugal, Romania, Slovakia, and Spain -- grow biotech crops at all (and not much). Their combined production amounts to less than one-thousandth of the world's total agricultural output.

Now, nearly 20 years after biotech crops debuted commercially, all of that may be about to change. A new policy being considered by the European Union will aim to give individual member nations more autonomy over the crops they cultivate, and clean up fragmented policies around the continent. That could be big news for plant-trait developers and biotech-seed producers such as Monsanto Company (NYSE:MON), Syngenta (NYSE:SYT) and The Dow Chemical Company (NYSE:DOW). Not only would they be able to sell engineered seeds directly to European farmers, but American farmers could gain an important market for exports. A policy shift could have major global economic advantages -- investors included! -- by the end of the decade.

The importance of European agriculture
China, South America, and the United States -- home to some of the world's best farmland -- have gladly taken the plunge with biotech crops, and have reaped significant rewards. Meanwhile, other leading breadbaskets such as Africa, the European Union, and Russia have largely refrained from cultivating biotech crops due to extreme caution, propaganda, and/or poor science. There would be profound consequences if any one of these leading agricultural regions pivoted, however, especially Europe. Consider the importance of European farmland for major world crops compared to other major regions:


No, Europe won't suddenly decide to plant large swaths of corn and soybeans if new policy is introduced, but we may see new traits and engineered seeds for the continent's staple crops, wheat and sugar beets. That could create a massive potential boon for Monsanto, Syngenta, and The Dow Chemical Company shareholders -- all of which actually have robust operations in Europe at the moment.


Monsanto Company 2013 Sales

Syngenta 2013 Sales

North America

$9.13 billion

$3.85 billion

Europe, Africa, Middle East

$2.04 billion

$4.22 billion

South America

$2.67 billion

$3.99 billion


$806 million

$1.93 billion



Total Sales

$14.9 billion

$13.99 billion*

*Excludes Lawn and Garden segment. Source: Monsanto Company, Syngenta.

Remember, each company can be broken down into two business segments: (1) seeds and traits, and (2) crop protection. Products and services offered to customers around the world include genetic traits, engineered seeds, "organic" seeds, agricultural oils, fungicides, insecticides, herbicides, and more. The growth I'm focusing on in this article would be derived from the ability to sell large quantities of traits and engineered seeds to the European market, although crop protection products would also come along for the ride.

By the numbers
How would it work? I envision growth in two parts. First, all three companies could capture continued growth for traits and seeds traditionally associated with American agriculture, such as corn and soybeans. Consider the breakdown of Monsanto Company's sales in the most recent fiscal year:


2013 Sales

% of Total Segment Sales

Corn Traits & Seeds

$6.6 billion


Soybean Traits & Seeds

$1.6 billion


Cotton Traits & Seeds

$700 million


Other Seeds & Traits

$575 million


Vegetable seeds

$821 million




Total Seed and Genomics Segment Sales

$10.34 billion


Source: SEC filings, Monsanto Company.

Syngenta boasts smaller sales in seeds and traits -- making most of its revenue from crop protection products -- but is an industry force nonetheless:


2013 Sales

% of Total Segment Sales

Corn and Soybean

$1.7 billion


Diverse Field Crops

$842 million



$708 million




Total Seed Segment Sales

$3.20 billion


Source: Syngenta (link opens PDF).

The Dow Chemical Company doesn't breakdown its agricultural business, Dow AgroSciences, but it has grown by at least 10% in each of the last three years, and sported total revenue of $7.14 billion in 2013. Since roughly 25% of the company's revenue was derived seeds, traits, and oils, let's use $1.7 billion for comparison to the companies above. Of course, it's important to stress that not all sales above are from engineered seeds; but you can see that the American agriculture market dominates -- and roughly dictates -- Monsanto Company's portfolio, and heavily influences those of its peers.

The second wave of growth would come from new traits altogether, tailored to the European market. Take wheat as the perfect example. While enhanced wheat varieties have failed to gain commercial traction in the United States -- North and South America account for just 17.5% of global wheat production -- in part due to import restrictions in Europe, the 28-member union, which accounts for one-third of global production, could turn the tide. New policy could open the door for genomic trait and seed companies to the massive global cereal market, which has been untouched by biotechnology. Most cereal production resides in Asia and Europe, but American farmers would gain an important and new market for exports. It would be a win-win for global agriculture.

Foolish bottom line
It's still amazing to think that the massive successes of the seed and trait segments at Monsanto Company, Syngenta, and The Dow Chemical Company have mostly come after the commercial use of biotech crops in 1996 -- starting from scratch with less defined tools and policies. The game is much different today.

Growth in Europe, whether from established or novel biotech products, could be expedited by leveraging relationships with existing customers -- assuming, of course, European farmers are interested. Acquisitions could be made to gain access to specific regions and markets, if necessary. It may sound a bit optimistic today, but it really isn't unrealistic to believe Europe could single-handedly change the world's attitude toward the marriage of biotechnology and agriculture. Savvy investors looking to global trading and market trends could stand to benefit.

Old agriculture tech may soon be worthless -- much like your credit card
Biotech crops have become an important agricultural tool for the world's farmers, and may soon push older, less-efficient production methods out of the market. Similar market forces are doing the same to credit cards. An eye-opening new presentation reveals the full story on why your credit card is about to be worthless -- and highlights one little-known company sitting at the epicenter of an earth-shaking movement that could hand early investors the kind of profits we haven't seen since the dot-com days. Click here to watch this stunning video.

Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolioCAPS pageprevious writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information